vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and PATHWARD FINANCIAL, INC. (CASH). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $173.1M, roughly 1.1× PATHWARD FINANCIAL, INC.). PATHWARD FINANCIAL, INC. runs the higher net margin — 20.3% vs 13.3%, a 7.0% gap on every dollar of revenue. On growth, PATHWARD FINANCIAL, INC. posted the faster year-over-year revenue change (-0.2% vs -1.8%). PATHWARD FINANCIAL, INC. produced more free cash flow last quarter ($104.1M vs $24.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -18.0%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Pathward Financial, Inc. is a U.S.-based banking and financial services company. It adopted its current name in 2022 after its parent, Meta Financial Group, sold the "Meta" trademark to Meta Platforms.
AMPH vs CASH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $173.1M |
| Net Profit | $24.4M | $35.2M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 24.6% |
| Net Margin | 13.3% | 20.3% |
| Revenue YoY | -1.8% | -0.2% |
| Net Profit YoY | -35.7% | 11.9% |
| EPS (diluted) | $0.51 | $1.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $173.1M | ||
| Q3 25 | $191.8M | $186.7M | ||
| Q2 25 | $174.4M | $195.8M | ||
| Q1 25 | $170.5M | $274.8M | ||
| Q4 24 | $186.5M | $182.6M | ||
| Q3 24 | $191.2M | $179.5M | ||
| Q2 24 | $182.4M | $188.6M | ||
| Q1 24 | $171.8M | $257.6M |
| Q4 25 | $24.4M | $35.2M | ||
| Q3 25 | $17.4M | $38.8M | ||
| Q2 25 | $31.0M | $42.1M | ||
| Q1 25 | $25.3M | $75.0M | ||
| Q4 24 | $38.0M | $30.0M | ||
| Q3 24 | $40.4M | $33.5M | ||
| Q2 24 | $37.9M | $44.9M | ||
| Q1 24 | $43.2M | $69.9M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 24.6% | ||
| Q3 25 | 13.2% | 25.9% | ||
| Q2 25 | 24.2% | 24.1% | ||
| Q1 25 | 21.9% | 33.2% | ||
| Q4 24 | 24.2% | 19.8% | ||
| Q3 24 | 29.8% | 20.9% | ||
| Q2 24 | 30.3% | 27.1% | ||
| Q1 24 | 27.9% | 33.8% |
| Q4 25 | 13.3% | 20.3% | ||
| Q3 25 | 9.0% | 20.8% | ||
| Q2 25 | 17.8% | 21.5% | ||
| Q1 25 | 14.8% | 27.3% | ||
| Q4 24 | 20.4% | 16.4% | ||
| Q3 24 | 21.1% | 18.7% | ||
| Q2 24 | 20.8% | 23.8% | ||
| Q1 24 | 25.1% | 27.1% |
| Q4 25 | $0.51 | $1.57 | ||
| Q3 25 | $0.37 | $1.69 | ||
| Q2 25 | $0.64 | $1.81 | ||
| Q1 25 | $0.51 | $3.14 | ||
| Q4 24 | $0.74 | $1.23 | ||
| Q3 24 | $0.78 | $1.34 | ||
| Q2 24 | $0.73 | $1.78 | ||
| Q1 24 | $0.81 | $2.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $331.2M |
| Total DebtLower is stronger | $608.7M | $33.5M |
| Stockholders' EquityBook value | $788.8M | $854.5M |
| Total Assets | $1.6B | $7.6B |
| Debt / EquityLower = less leverage | 0.77× | 0.04× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $331.2M | ||
| Q3 25 | $276.2M | $120.6M | ||
| Q2 25 | $231.8M | $258.3M | ||
| Q1 25 | $236.9M | $254.2M | ||
| Q4 24 | $221.6M | $597.4M | ||
| Q3 24 | $250.5M | $158.3M | ||
| Q2 24 | $217.8M | $298.9M | ||
| Q1 24 | $289.6M | $347.9M |
| Q4 25 | $608.7M | $33.5M | ||
| Q3 25 | $608.6M | $33.5M | ||
| Q2 25 | $607.7M | $33.4M | ||
| Q1 25 | $603.9M | $33.4M | ||
| Q4 24 | $601.6M | $33.4M | ||
| Q3 24 | $596.4M | $33.4M | ||
| Q2 24 | $586.9M | $33.3M | ||
| Q1 24 | $594.0M | $33.4M |
| Q4 25 | $788.8M | $854.5M | ||
| Q3 25 | $776.7M | $858.0M | ||
| Q2 25 | $757.5M | $819.0M | ||
| Q1 25 | $751.3M | $814.7M | ||
| Q4 24 | $732.3M | $758.3M | ||
| Q3 24 | $727.7M | $822.5M | ||
| Q2 24 | $713.3M | $748.4M | ||
| Q1 24 | $672.4M | $719.5M |
| Q4 25 | $1.6B | $7.6B | ||
| Q3 25 | $1.7B | $7.2B | ||
| Q2 25 | $1.6B | $7.2B | ||
| Q1 25 | $1.6B | $7.0B | ||
| Q4 24 | $1.6B | $7.6B | ||
| Q3 24 | $1.5B | $7.5B | ||
| Q2 24 | $1.5B | $7.5B | ||
| Q1 24 | $1.6B | $7.4B |
| Q4 25 | 0.77× | 0.04× | ||
| Q3 25 | 0.78× | 0.04× | ||
| Q2 25 | 0.80× | 0.04× | ||
| Q1 25 | 0.80× | 0.04× | ||
| Q4 24 | 0.82× | 0.04× | ||
| Q3 24 | 0.82× | 0.04× | ||
| Q2 24 | 0.82× | 0.04× | ||
| Q1 24 | 0.88× | 0.05× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $108.3M |
| Free Cash FlowOCF − Capex | $24.6M | $104.1M |
| FCF MarginFCF / Revenue | 13.4% | 60.1% |
| Capex IntensityCapex / Revenue | 4.5% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.35× | 3.08× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $616.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $108.3M | ||
| Q3 25 | $52.6M | $303.7M | ||
| Q2 25 | $35.6M | $30.4M | ||
| Q1 25 | $35.1M | $188.3M | ||
| Q4 24 | $29.0M | $-71.7M | ||
| Q3 24 | $60.0M | $143.1M | ||
| Q2 24 | $69.1M | $113.2M | ||
| Q1 24 | $55.3M | $203.0M |
| Q4 25 | $24.6M | $104.1M | ||
| Q3 25 | $47.2M | $300.3M | ||
| Q2 25 | $25.0M | $27.7M | ||
| Q1 25 | $24.4M | $184.7M | ||
| Q4 24 | $16.6M | $-73.8M | ||
| Q3 24 | $46.2M | $138.8M | ||
| Q2 24 | $63.1M | $111.0M | ||
| Q1 24 | $46.5M | $201.3M |
| Q4 25 | 13.4% | 60.1% | ||
| Q3 25 | 24.6% | 160.9% | ||
| Q2 25 | 14.3% | 14.1% | ||
| Q1 25 | 14.3% | 67.2% | ||
| Q4 24 | 8.9% | -40.4% | ||
| Q3 24 | 24.1% | 77.3% | ||
| Q2 24 | 34.6% | 58.8% | ||
| Q1 24 | 27.1% | 78.1% |
| Q4 25 | 4.5% | 2.4% | ||
| Q3 25 | 2.8% | 1.8% | ||
| Q2 25 | 6.1% | 1.4% | ||
| Q1 25 | 6.3% | 1.3% | ||
| Q4 24 | 6.7% | 1.1% | ||
| Q3 24 | 7.2% | 2.4% | ||
| Q2 24 | 3.3% | 1.2% | ||
| Q1 24 | 5.1% | 0.7% |
| Q4 25 | 1.35× | 3.08× | ||
| Q3 25 | 3.03× | 7.83× | ||
| Q2 25 | 1.15× | 0.72× | ||
| Q1 25 | 1.39× | 2.51× | ||
| Q4 24 | 0.76× | -2.39× | ||
| Q3 24 | 1.48× | 4.27× | ||
| Q2 24 | 1.82× | 2.52× | ||
| Q1 24 | 1.28× | 2.90× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
CASH
| Consumer | $103.0M | 59% |
| Payment Card And Deposit Fees | $30.1M | 17% |
| Other | $24.2M | 14% |
| Rental Income | $11.6M | 7% |
| Commercial | $4.2M | 2% |
